Drugs / MK-7762
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05824091 | Feb 2023 → Mar 2024 | tuberculosis | Gates Medical Research Institute | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-7762 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05824091 ↗ |
| Known as | TBD09 | “The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics of single and then multiple doses of MK-7762 (TBD09) in healthy volunteers in the...” NCT05824091 ↗ |
| Route | Oral | “The effect of food on the rate and extent of absorption of a single oral dose of MK-7762 (TBD09) will also be evaluated.” NCT05824091 ↗ |